Codagenix, Co-founded by FSC Professor, Receives $20 Million Funding

February 3, 2020

Dr. J. Robert Coleman

Codagenix, a clinical-stage biotechnology company developing prophylactic vaccines and oncolytic virus therapies, and headed by Dr. J. Robert Coleman, CEO and professor in the Biology department, has closed a $20 million Series B investment to continue development of live attenuated RSV vaccine for the elderly, a broadly-protective influenza vaccine, and an oncolytic virus therapy for triple-negative breast cancer.

The investment was led by Adjuvant Capital, a venture capital firm that incubated at Gates Global Health Initiative, with the participation of other investors, TopSpin Partners and Euclidean Capital.

Codagenix was founded by Dr. Coleman, CSO, Dr. Steffen Mueller, and Stony Brook University Distinguished Professor Eckard Wimmer. The goals of the high-tech start-up are to:

commercialize viral design technology developed by Dr. Wimmer,
answer the unmet need for more effective vaccines, and increased treatment options for cancer.

Codagenix has nine employees, and is headquartered at Broad Hollow Bioscience Park, at FSC,

“Our mission is to improve human health by commercializing our technology to make better, more effective vaccines,” says Dr. Coleman.